Androgen Deprivation Therapy

How to Best Select Doublet vs. Triplet Therapy in MCSPC

Scott B. Sellinger, MD, FACS, addresses doublet and triplet therapies for metastatic castration-sensitive prostate cancer.

Cardiometabolic Health for Men with Advanced Prostate Cancer: Lessons Learned and Future Directions

Andrew W. Hahn, MD, addresses cardiometabolic health in men with advanced prostate cancer.

An Expert Discussion of Testosterone Nadir and Clinical Outcomes in Patients with Advanced Prostate Cancer: A Post Hoc Analysis of Triptorelin Pamoate Phase III Studies

ADT is the Building Block for Advanced Prostate Cancer Therapy

E. David Crawford, MD; Scott B. Sellinger, MD; & David S. Morris, MD, FACS, discuss ADT as a foundational therapy for PCa.

ADT as Foundational Therapy, and the Need for Consensus on Consistent T Suppression, Goals, Monitoring, and Delaying Time to CRPC

E. David Crawford, MD; Neal D. Shore, MD, FACS; & Benjamin H. Lowentritt, MD, FACS, discuss ADT as a foundational therapy for PCa.

ADT Side Effects: Cardiovascular Disease

These lectures were presented during the Perspectives in Urology Point-Counterpoint Virtual Conference on November 11, 2020.

Reinforcing Consistent Testosterone Suppression in ADT

E. David Crawford, MD, Scott B. Sellinger, MD, and Paul R. Sieber, MD, discuss reinforcing consistent testosterone suppression in ADT and the role of triptorelin.